Vir Biotechnology (VIR) Competitors

Vir Biotechnology (NASDAQ:VIR) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.

Do analysts rate VIR or AKRO?

Vir Biotechnology presently has a consensus target price of $33.57, suggesting a potential upside of 448.55%. Akero Therapeutics has a consensus target price of $76.29, suggesting a potential upside of 67.26%. Given Vir Biotechnology's higher possible upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Akero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, VIR or AKRO?

Akero Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Akero Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$63.71M	13.26	-$615.06M	-$3.82	-1.60
Akero Therapeutics	N/A	N/A	-$151.76M	-$3.75	-12.16

Does the MarketBeat Community believe in VIR or AKRO?

Akero Therapeutics received 60 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 65.36% of users gave Akero Therapeutics an outperform vote while only 56.44% of users gave Vir Biotechnology an outperform vote.

Company	Underperform	Outperform
Vir Biotechnology	Outperform Votes 57 56.44%	Underperform Votes 44 43.56%
Akero Therapeutics	Outperform Votes 117 65.36%	Underperform Votes 62 34.64%

Which has more volatility & risk, VIR or AKRO?

Vir Biotechnology has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in VIR or AKRO?

65.3% of Vir Biotechnology shares are owned by institutional investors. 15.6% of Vir Biotechnology shares are owned by company insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media favor VIR or AKRO?

In the previous week, Akero Therapeutics had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for Akero Therapeutics and 7 mentions for Vir Biotechnology. Akero Therapeutics' average media sentiment score of 1.21 beat Vir Biotechnology's score of 0.65 indicating that Akero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akero Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is VIR or AKRO more profitable?

Akero Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Akero Therapeutics' return on equity of -32.46% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-678.40%	-36.71%	-31.00%
Akero Therapeutics	N/A	-32.46%	-29.83%

Summary

Akero Therapeutics beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.